The United States Food and Drug Administration (USFDA) has concluded the inspection at Cipla’s manufacturing facility in Virgonagar, Bengaluru. The inspection was conducted from 7th - 13th November 2024.

On conclusion of the inspection, the Company received 8 observations in Form 483. The Company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.